Operator: Good evening. My name is Terri, and I will be your conference operator today. At this time, I would like to welcome everyone to the XenoPort Fourth Quarter Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. Thank you.
I will now turn the conference over to Ms. Jackie Cossmon of XenoPort.
Jackie Cossmon - IR: Thank you, Terri. Good afternoon and thank you for joining us on the call. Here with me today are Ron Barrett, our Chief Executive Officer; Bill Harris, our Senior Vice President of Finance and Chief Financial Officer; and Vince Angotti, our Chief Operating Officer.
Before we begin our discussion of today's news, I would like to note that the information to be discussed on this conference call and webcast, including answers to questions asked during this call, will include forward-looking statements that involve risks and uncertainties, including all statements related to future sales of and all commercialization and promotional plans and activities for Horizant, our current and future clinical development programs and clinical trials, the release of additional clinical trial data and the timing thereof, potential advantages of our product candidates, regulatory actions and submissions, our dependence on our collaborative partner, future sales of Regnite, the therapeutic and commercial potential of gabapentin enacarbil and our product candidates, and financial guidance. XenoPort can give no assurance with respect to these statements and we assume no obligation to update them.
For detailed information about the risks and uncertainties that could cause actual results to differ materially from those implied by or anticipated in these forward-looking statements, please refer to the Risk Factor section of our most recent SEC filings, including our discussions of inherent risks of clinical trials and regulatory matters.
This webcast is a copyright of XenoPort. At this time, I would like to turn the presentation over to Ron.
Ronald W. Barrett - CEO: Thanks, Jackie. Good afternoon and thank you all for joining us today. 2012 was an important year for XenoPort and has set up 2013 as a transformational year for the Company. I'll be summarizing our progress in 2012 and describing our development plans for 2013. An important event that occurred in November last year was the reacquisition of the rights to Horizant, and we've been busy preparing to commercialize Horizant starting May 1. Vince will describe our commercial preparation and plans, and then Bill will discuss the financials for the fourth quarter and what we expect financially going forward.
The reacquisition of Horizant represents an exciting opportunity for XenoPort and marks the important transition of the Company into a commercial entity. There remain substantial unmet medical needs in the treatment of moderate-to-severe primary restless legs syndrome, which we'll be referring to as RLS, and the management of postherpetic neuralgia, which we'll refer to as PHN. We look forward to educating key stakeholders about the value of Horizant starting May 1st.